Literature DB >> 21604021

Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.

Sarah Schott1, Markus Wallwiener, Beate Kootz, Harald Seeger, Tanja Fehm, Hans Neubauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21604021     DOI： 10.1007/s10637-011-9688-3

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  21 in total

1.  A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.

Authors:  Monica M Reinholz; Shawn P Zinnen; Amylou C Dueck; David Dingli; Gregory G Reinholz; Leslie A Jonart; Kathleen A Kitzmann; Amy K Bruzek; Vivian Negron; Abdalla K Abdalla; Bonnie K Arendt; Anthony J Croatt; Luis Sanchez-Perez; David P Sebesta; Harri Lönnberg; Toshiyuki Yoneda; Karl A Nath; Diane F Jelinek; Stephen J Russell; James N Ingle; Thomas C Spelsberg; Henry B F Hal Dixon; Alexander Karpeisky; Wilma L Lingle
Journal:  Bone       Date:  2010-03-15       Impact factor: 4.398

2.  ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.

Authors:  Sarah Schott; Markus Wallwiener; Beate Kootz; Harald Seeger; Tanja Fehm; Hans Neubauer
Journal:  Invest New Drugs       Date:  2009-12-09       Impact factor: 3.850

3.  The cytostatic effect of 9-cis-retinoic acid, tretinoin, and isotretinoin on three different human bladder cancer cell lines in vitro.

Authors:  S Laaksovirta; P Rajala; M Nurmi; T L Tammela; M Laato
Journal:  Urol Res       Date:  1999

4.  Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.

Authors:  G Konecny; C Crohns; M Pegram; M Felber; S Lude; C Kurbacher; I A Cree; H Hepp; M Untch
Journal:  Gynecol Oncol       Date:  2000-05       Impact factor: 5.482

5.  Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.

Authors:  Louise A Knight; Mark Conroy; Augusta Fernando; Marta Polak; Christian M Kurbacher; Ian A Cree
Journal:  Anticancer Drugs       Date:  2005-10       Impact factor: 2.248

Review 6.  Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.

Authors:  Hideki Hirabayashi; Jiro Fujisaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro.

Authors:  L Kangas; M Grönroos; A L Nieminen
Journal:  Med Biol       Date:  1984

8.  Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.

Authors:  Hans Neubauer; Maya Stefanova; Erich Solomayer; Christoph Meisner; Manfred Zwirner; Diethelm Wallwiener; Tanja Fehm
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

9.  Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.

Authors:  P E Andreotti; I A Cree; C M Kurbacher; D M Hartmann; D Linder; G Harel; I Gleiberman; P A Caruso; S H Ricks; M Untch
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

Review 10.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

Authors:  M Aapro; P A Abrahamsson; J J Body; R E Coleman; R Colomer; L Costa; L Crinò; L Dirix; M Gnant; J Gralow; P Hadji; G N Hortobagyi; W Jonat; A Lipton; A Monnier; A H G Paterson; R Rizzoli; F Saad; B Thürlimann
Journal:  Ann Oncol       Date:  2007-09-28       Impact factor: 32.976
View more
  4 in total

Review 1.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

2.  In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis.

Authors:  Sarah Schott; Sonia Vallet; Robert J Tower; Seema Noor; Sanjay Tiwari; Christian Schem; Christian Busch
Journal:  Invest New Drugs       Date:  2015-05-20       Impact factor: 3.850

Review 3.  Bisphosphonate conjugation for bone specific drug targeting.

Authors:  Kristen B Farrell; Alexander Karpeisky; Douglas H Thamm; Shawn Zinnen
Journal:  Bone Rep       Date:  2018-07-03

Review 4.  Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer.

Authors:  Zintle Mbese; Blessing A Aderibigbe
Journal:  Int J Mol Sci       Date:  2021-06-26       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.